dailynewsnblog
June 9 (Reuters) – GSK has agreed to buy cancer drug developer Nuvalent for $10.6 billion in its biggest deal in years, as the British drugmaker looks to bolster its pipeline and support long-term revenue growth.
The move adds to a growing list of high-profile transactions over the past decade by U.S. pharmaceutical companies to acquire promising therapies in fields ranging from oncology, neurology to rare diseases and obesity.
Below are some of the major deals involving U.S.-based pharma and biotech firms from the past decade
Year Acquirer Target Deal Description
Value
2026 GSK Nuvalent $10.6 To expand
billion late-stage
cancer drug
pipeline
2026 Boston Penumbra $14.5 To expand
Scientific billion vascular
pipeline
2025 Abbott Exact up to $23 To gain
Sciences billion access to
Exact
Sciences’
cancer tests,
including
flagship
colorectal
cancer test
Cologuard
2025 Merck Cidara $9.2 To gain
Therapeut billion access to
ics Cidara’s
experimental
drug for flu
prevention
2025 Pfizer Metsera $10 To gain a
billion foothold in
the
fast-growing
obesity
treatment
market
2025 Merck & Verona About $10 Strengthens
Co Pharma billion Merck’s
respiratory
portfolio
amid looming
Keytruda
patent cliff
2025 Johnson & Intra-Cel $14.6 Expands J&J’s
Johnson lular billion footprint in
Therapies brain disease
treatments
2024 Novo Catalent $16.5 Boosts
Holdings billion manufacturing
(includin capacity for
g debt), Novo
$11.5 Nordisk’s
billion popular
(excludin obesity drug
g debt) Wegovy
2023 Merck & Prometheu $10.8 Adds
Co s billion experimental
Bioscienc treatment for
es ulcerative
colitis and
Crohn’s
disease and
builds up
presence in
immunology
2023 Bristol Karuna $14 BMY gains a
Myers Therapeut billion promising
Squibb ics antipsychotic
medicine as
patents on
its older
therapies
near their
expiry
2023 Pfizer Seagen $43 Builds
billion Pfizer’s
cancer
portfolio
amid decline
in sales for
COVID-related
products and
generic
competition
2022 Amgen Horizon $27.8 Buyout,
Therapeut billion biggest in
ics the sector in
2022,
fortifies
rare diseases
portfolio
2022 Pfizer Biohaven $11.6 Pfizer bets
Pharmaceu billion big on a new
tical class of
Holding migraine
drugs
2021 Merck & Co Acceleron About Diversifies
Pharma $11.5 Merck’s
billion portfolio
beyond
cancer
2021 Ginkgo Soaring $17.5 Ginkgo goes
Bioworks Eagle million public
Acquisiti through a
on merger with a
blank-check
vehicle
backed by
former
Hollywood
executives
Harry Sloan
and Jeff
Sagansky
2020 AstraZenec Alexion $39 AstraZeneca’s
a Pharmaceu billion largest ever
ticals deal to
diversify
away from its
cancer
business,
betting on
rare-disease
and
immunology
